Understanding the functions of LKB1 and other protein kinases mutated in inherited diseases

Lead Research Organisation: MRC Protein Phosphorylation Unit

Abstract

Recent clinical studies have identified alterations in genes that encode enzymes called kinases, which cause diseases such cancer, hypertension and Parkinsons disease. Little is known about how these kinases operate in normal cells and our research is aimed at understanding how their alteration leads to disease. One such kinase is LKB1, which is altered in some forms of cancer. Recently, we made the unexpected discovery that LKB1 mimics the action of metformin, the drug that is used most commonly to treat type 2 diabetes. This led us to undertake a preliminary clinical study, which has indicated that diabetics in the Tayside region of Scotland who are prescribed metformin, have a reduced risk of developing cancer.||We now plan to extend our work to understand the role that LKB1 plays in cancer and to further explore the utility of metformin as an anti-cancer target. We also plan to study the functions of other kinases that are altered in different diseases, such as hypertension and early-onset Parkinsons disease. We expect this to provide new fundamental information that will facilitate the development of improved drugs to treat these debilitating diseases in the future.

Technical Summary

Protein kinases are the largest family of enzymes encoded by the human genome and their role is to catalyse the covalent attachment of phosphate to specific amino acid residues in target proteins. This modifies the functions of the target proteins and hence the physiological processes in which they participate. A highlight of our recent research has been the discovery of how the protein kinase LKB1 works. We found that, to be active, LKB1 must exist as a complex with two other proteins, termed STRAD and MO25. This allows LKB1 to activate AMPK, another protein kinase that is the major sensor of the energy status of living cells. Intriguingly metformin, the most widely prescribed drug to treat Type 2-diabetes, also exerts its effects by activating AMPK. By creating a strain of mice that do not express LKB1 in muscle, we were able to demonstrate that LKB1 and AMPK regulate the uptake of glucose into muscle during exercise. These finding were most unexpected, since the gene encoding LKB1 is mutated in Peutz-Jegers syndrome, an inherited disease that predisposes to multiple cancers, implying that LKB1 functions as a tumour suppressor in cells. We therefore wondered whether metformin, might not only have efficacy for the treatment of diabetes, but also for the treatment or prevention of cancer. Excitingly, a pilot epidemiology-based study involving a few thousand patients, which was undertaken in collaboration with Andrew Morris, Professor of Diabetic Medicine at Dundee, has indicated that diabetic patients in the Tayside region of Scotland have a significantly reduced risk of developing cancer if they are taking metformin. We have also demonstrated that LKB1 not only activates AMPK, but 12 other related protein kinases. These include protein kinases that control cell polarity and have been implicated in producing neurofibrillary tangles, which are the deposits found in the brains of patients with Alzheimers disease. Our future studies will focus on defining the cellular functions of the protein kinases that are activated by LKB1, which are poorly understood at present. We also plan to understand the roles of other poorly characterised protein kinases, whose mutation in humans results in inherited diseases. These include the WNK1 and WNK4 genes that are mutated in patients with Gordons syndrome, an inherited hypertension syndrome, as well as the PINK1 and LRRK2 genes, which are mutated in people with early onset Parkinsons disease. These studies have the potential to lead to the discovery of new regulatory pathways of relevance to the understanding of human disease.

Publications

10 25 50
 
Description A systematic investigation into the pathogenesis and course of Paskinson's syndrome
Amount £300,000 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 01/2010 
End 01/2015
 
Description Assessment of LRRK2 activity in G2385R carriers
Amount £57,771 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 08/2018 
End 07/2019
 
Description CRUK Project Grant - Molecular mechanisms of assembly, regulation and substrate recognition of the heterotrimeric LKB1 tumour suppressor
Amount £178,806 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2009 
End 01/2012
 
Description Equipment Grant
Amount £205,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2013 
End 03/2014
 
Description Equipment Grant for our mid career investigators
Amount £54,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2013 
End 03/2014
 
Description Equipment grant
Amount £260,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description Exploiting Ser910/935 phosphorylation and 14-3-3 binding to develop biomarkers for LRRK2 activity
Amount £120,431 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2010 
End 01/2012
 
Description Generation of Phospho-Ser65 Parkin and Phospho-Thr257 PINK1 rabbit monoclonal antibodies and characterisation of Total PINK1 rabbit and mouse monoclonal antibodies
Amount $18,552 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 05/2012 
End 04/2013
 
Description Genome wide screens to uncover novel upstream regulators of LRRK2
Amount £305,944 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description Impact of Shared Crohn's disease
Amount £55,444 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 11/2018 
End 10/2019
 
Description Industrially supported Postdoc collaboration
Amount £303,948 (GBP)
Organisation Johnson & Johnson 
Department Janssen Pharmaceuticals
Sector Private
Country United States
Start 01/2011 
End 01/2014
 
Description J MacDonald Menzies
Amount £177,000 (GBP)
Organisation J Macdonald Menzies Charitable Trust 
Sector Charity/Non Profit
Country Unknown
Start  
 
Description Kinase Profiling Services
Amount £1,582,000 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 03/2013 
End 02/2018
 
Description LEAPS Award to identify LRRK2 substrates
Amount $1,500,000 (USD)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 02/2012 
End 01/2015
 
Description Lanston Award
Amount £17,582 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2018 
End 12/2019
 
Description Mass-spectrometry based global analysis of protein phosphorylation in cells and tissue extracts with altered PINK1 catalytic activity: a novel screen for PINK1 substrates
Amount £84,945 (GBP)
Funding ID H-0901 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2009 
End 01/2012
 
Description PhD Studentship
Amount £146,000 (GBP)
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2011 
End 01/2015
 
Description Project Grant
Amount £56,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2012 
End 01/2013
 
Description Project Grant:
Amount £161,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2011 
End 01/2013
 
Description Project grant
Amount £23,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description Project grant
Amount £122,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description Project grant
Amount £93,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description Project grant
Amount £63,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description QQ Renewal
Amount £25,590,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description Rab LEAPs Renewal
Amount £332,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 08/2018 
End 07/2020
 
Description Rapid Innovation Award - Identification of substrates and development of a cell-based assay for LRRK2
Amount £46,500 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2009 
End 01/2010
 
Description Renewal of Division of Signal Transduction Therapy Unit
Amount £7,200,000 (GBP)
Organisation Dundee Signal Transduction Therapy (DSTT) Consortium 
Sector Academic/University
Country United Kingdom
Start  
 
Description Renewal of MRC Protein Phosphorylation and Ubiquitylation Core Funding
Amount £24,000,000 (GBP)
Funding ID Purchase Order Number: 4050295594 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2013 
End 03/2018
 
Description Renewal of MRC-PPU quinquenial funding
Amount £23,100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2013 
End 03/2018
 
Description Tools Development
Amount £83,244 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 10/2018 
End 09/2020
 
Description Tools and Animal Models
Amount £54,902 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 07/2018 
End 12/2019
 
Description Understanding LRRK2 2 year project grant to fund postdoc in lab
Amount £130,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2010 
End 01/2012
 
Description Wellcome Trust Collaborative Projects (Modulation of renal NaCl transporter via angiotensin II-WNK4-SPAK signalling pathway)
Amount £230,172 (GBP)
Funding ID 091415 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2010 
End 01/2013
 
Title Development of novel state of the art phospho-specific Rabbit monoclonal antibodies to studdy LRRK2 mediated phosphorylation of Rab proteins in Parkinson's disease 
Description Mutations that activate the LRRK2 (leucine-rich repeat protein kinase 2) protein kinase predispose to Parkinson's disease, suggesting that LRRK2 inhibitors might have therapeutic benefit. Our recent work has revealed that LRRK2 phosphorylates a subgroup of 14 Rab proteins, including Rab10, at a specific residue located at the centre of its effector-binding switch-II motif. In the present study, we analyse the selectivity and sensitivity of polyclonal and monoclonal phospho-specific antibodies raised against nine different LRRK2-phosphorylated Rab proteins (Rab3A/3B/3C/3D, Rab5A/5B/5C, Rab8A/8B, Rab10, Rab12, Rab29[T71], Rab29[S72], Rab35 and Rab43). We identify rabbit monoclonal phospho-specific antibodies (MJFF-pRAB10) that are exquisitely selective for LRRK2-phosphorylated Rab10, detecting endogenous phosphorylated Rab10 in all analysed cell lines and tissues, including human brain cingulate cortex. We demonstrate that the MJFF-pRAB10 antibodies can be deployed to assess enhanced Rab10 phosphorylation resulting from pathogenic (R1441C/G or G2019S) LRRK2 knock-in mutations as well as the impact of LRRK2 inhibitor treatment. We also identify rabbit monoclonal antibodies displaying broad specificity (MJFF-pRAB8) that can be utilised to assess LRRK2-controlled phosphorylation of a range of endogenous Rab proteins, including Rab8A, Rab10 and Rab35. The antibodies described in the present study will help with the assessment of LRRK2 activity and examination of which Rab proteins are phosphorylated in vivo These antibodies could also be used to assess the impact of LRRK2 inhibitors in future clinical trials. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact All companies and researchers investigating LRRK2 are now using our technology. A company called Denali has just launched the first clinical trials for LRRK2 inhibitors and are using our reagents for their monitoring efficacy of LRRK2 inhibitors. Many other companies are likely to follow suit 
 
Title development of SPAK knock-in mice 
Description Non-WNK-activatable Spak knock-in mice have reduced blood pressure and therefore suggests that inhibitors of SPAK could be developed to treat blood pressure 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2009 
Provided To Others? Yes  
Impact None as yet 
 
Title new assay to quantify LRRK2 kinase activity 
Description We have developped a new assay to quamtify LRRK2 kinase activity 
Type Of Material Technology assay or reagent 
Year Produced 2009 
Provided To Others? Yes  
Impact Many groups worldwide are using our assay for LRRK2 and the MRC patented this assay in 2008. Further data has been added to MRC patent this year to strengthen it 
 
Description Aaron M 
Organisation University of Manitoba
Department Department of Immunology
Country Canada 
Sector Academic/University 
PI Contribution Provision of TAPP1 and TAPP2 knock-in mice
Collaborator Contribution Studying impact of TAPP1 and TAPP2 mutations in B cell signalling responses
Impact Jayachandran, N., Landego, I., Hou, S., Alessi, D. R. and Marshall, A. J. (2016). B-cell-intrinsic function of TAPP adaptors in controlling germinal center responses and autoantibody production in mice. Eur J Immunol Landego, I., Jayachandran, N., Wullschleger, S., Zhang, T. T., Gibson, I. W., Miller, A., Alessi, D. R. and Marshall, A. J. (2012). Interaction of TAPP adapter proteins with phosphatidylinositol (3,4)-bisphosphate regulates B-cell activation and autoantibody production. Eur J Immunol 42, pp. 2760-2770
Start Year 2011
 
Description Andy C 
Organisation Redx Pharma Plc
Country United Kingdom 
Sector Private 
PI Contribution Provision of reagents technolgy and advice to better study SGK biology in cancer
Collaborator Contribution Use of our expertise and technology and reagents to identify improved inhibitors of the SGK protein kinase
Impact .
Start Year 2015
 
Description Became a member of Wellcome Trust-MRC funded UK Parkinson's disease initiative 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution We undertake the biochemical and siganlling analysis of this part of the collaboration
Collaborator Contribution This has provided us with vital clinical links to the best UK Pakinson's disease clinical researchers (Nick Wood, Tony Schapiro and John Hardy) at the world faous institute of Neurology. Alex Withworth from Sheffield University is also a member of this consortium. This is the first time in the UL that a large group of researchers with complementary expertise has been brought together to combat Parkinson's disease
Impact This collaboration has just started but numerous collaborations are underway and we hope to have more tangiable outputs to report soon
Start Year 2010
 
Description Christian P 
Organisation University of Kiel
Department Department of Pharmaceutical Chemistry
Country Germany 
Sector Academic/University 
PI Contribution Undertaking kinase assays to assess effects of novel light sensitive kinase inhibitors
Collaborator Contribution development of novel light sensitive kinase inhibitors
Impact Horbert, R., Pinchuk, B., Davies, P., Alessi, D. and Peifer, C. (2015). Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib. ACS Chem Biol 10, pp. 2099-2107
Start Year 2015
 
Description Collaboration with Daan van Aalten of structural analysis of the LKB1 tumour supressor 
Organisation University of Dundee
Department Department of Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution We have expressed the LKB1 tumour supressor complex and Daan van Aaltens lab have crytallised this. This is a spectacular piece of work that reveals the molecular mechanism by which the LKB1 tumour supressor is activated and how mutations in this enzyme can lead to cancer
Collaborator Contribution Our Collaboration with Daan vaan Aalten has resulted in the award of a Cancer Research Uk grant to Daan's lab to fund a postdoc for 3 years to continue this work
Impact This work has resulted in 2 major papers in 2009 one in the journal PLOS BIOLOGY (PMID: 19513107) and the other in Science (PMID: 19892943).
 
Description D Saur 
Organisation Technical University of Munich
Country Germany 
Sector Academic/University 
PI Contribution advice and reagents and techical support
Collaborator Contribution analysed effect of kinase inhibitors and mutations in various models of human tumours
Impact Schonhuber, N., Seidler, B., Schuck, K., Veltkamp, C., Schachtler, C., Zukowska, M., Eser, S., Feyerabend, T. B., Paul, M. C., Eser, P., Klein, S., Lowy, A. M., Banerjee, R., Yang, F., Lee, C. L., Moding, E. J., Kirsch, D. G., Scheideler, A., Alessi, D. R., Varela, I., Bradley, A., Kind, A., Schnieke, A. E., Rodewald, H. R., Rad, R., Schmid, R. M., Schneider, G. and Saur, D. (2014). A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nat Med 20, pp. 1340-1347 Eser, S., et al including Alessi, D. R. and Saur, D. (2013). Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer. Cancer Cell 23, pp. 406-420
Start Year 2012
 
Description DSTT 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution All the Programme Leaders in the MRC Protein Phosphorylation Unit have participated in a major collaboration with the pharmaceutical industry since 1998, termed The Division of Signal Transduction Therapy. From July 2003 to July 2008, the participating pharmaceutical companies were AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co, Merck-Serono and Pfizer. The collaboration was renewed for a further four years in July 2008 with five of these companies (Merck and Co leaving the consortium at this time). This collaboration was renewed for an unprecedented fourth time in July 2013 for a further four years with six pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janessen Pharmaceutica), Merck-Serono and Pfizer. Each of the six companies pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease. For more information see http://www.ppu.mrc.ac.uk/overview/DSTT.php
Collaborator Contribution Benefits from DSTT collaboration The MRC-PPU benefits in many ways as a result of the DSTT research collaboration. 1. It provides an obvious translational outlet to enable our PIs to exploit their research findings. For example, any PI within the MRC-PPU can rapidly let all six pharmaceutical companies know about any new potential exciting research finding that they have made or any drug target that they have identified or validated. This can lead to major collaborations and stimulate one or more of the pharmaceutical companies to initiate a new drug discovery programme. 2. The research support received from this collaboration is invested in the PPU PIs research programmes and provides additional support to several of our Unit's Scientific service teams including our protein production teams, antibody generation team and cloning team. 3. We obtain key reagents including novel inhibitors, genetically modified cell or mice models from our DSTT pharmaceutical company collaborators. 4. The pharmaceutical companies we collaborate with provide us with important knowledge on the most critical research issues of the day for their drug development programmes. This feedback and industry perspective is extremely useful and helps maximise our overall competitiveness. It ensures that the drug discovery research programmes of the PPU PIs are focussed on addressing the most important questions for better understanding and treating disease. 5. The DSTT collaboration greatly benefits our students and postdocs by providing experience in working with industry via their direct involvement in collaborative experiments with pharmaceutical companies. This provides them with a unique insight into the high quality cutting edge research that is taking place within pharmaceutical companies and gives them an awareness of potential careers in industry. This is particularly important given that one of our main priorities is to train tomorrow's industrial researchers and ensure that the future workforce has the high quality scientific and research support skills that the UK economy will be dependent on.
Impact During the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
 
Description DSTT 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution All the Programme Leaders in the MRC Protein Phosphorylation Unit have participated in a major collaboration with the pharmaceutical industry since 1998, termed The Division of Signal Transduction Therapy. From July 2003 to July 2008, the participating pharmaceutical companies were AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co, Merck-Serono and Pfizer. The collaboration was renewed for a further four years in July 2008 with five of these companies (Merck and Co leaving the consortium at this time). This collaboration was renewed for an unprecedented fourth time in July 2013 for a further four years with six pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janessen Pharmaceutica), Merck-Serono and Pfizer. Each of the six companies pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease. For more information see http://www.ppu.mrc.ac.uk/overview/DSTT.php
Collaborator Contribution Benefits from DSTT collaboration The MRC-PPU benefits in many ways as a result of the DSTT research collaboration. 1. It provides an obvious translational outlet to enable our PIs to exploit their research findings. For example, any PI within the MRC-PPU can rapidly let all six pharmaceutical companies know about any new potential exciting research finding that they have made or any drug target that they have identified or validated. This can lead to major collaborations and stimulate one or more of the pharmaceutical companies to initiate a new drug discovery programme. 2. The research support received from this collaboration is invested in the PPU PIs research programmes and provides additional support to several of our Unit's Scientific service teams including our protein production teams, antibody generation team and cloning team. 3. We obtain key reagents including novel inhibitors, genetically modified cell or mice models from our DSTT pharmaceutical company collaborators. 4. The pharmaceutical companies we collaborate with provide us with important knowledge on the most critical research issues of the day for their drug development programmes. This feedback and industry perspective is extremely useful and helps maximise our overall competitiveness. It ensures that the drug discovery research programmes of the PPU PIs are focussed on addressing the most important questions for better understanding and treating disease. 5. The DSTT collaboration greatly benefits our students and postdocs by providing experience in working with industry via their direct involvement in collaborative experiments with pharmaceutical companies. This provides them with a unique insight into the high quality cutting edge research that is taking place within pharmaceutical companies and gives them an awareness of potential careers in industry. This is particularly important given that one of our main priorities is to train tomorrow's industrial researchers and ensure that the future workforce has the high quality scientific and research support skills that the UK economy will be dependent on.
Impact During the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
 
Description DSTT 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution All the Programme Leaders in the MRC Protein Phosphorylation Unit have participated in a major collaboration with the pharmaceutical industry since 1998, termed The Division of Signal Transduction Therapy. From July 2003 to July 2008, the participating pharmaceutical companies were AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co, Merck-Serono and Pfizer. The collaboration was renewed for a further four years in July 2008 with five of these companies (Merck and Co leaving the consortium at this time). This collaboration was renewed for an unprecedented fourth time in July 2013 for a further four years with six pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janessen Pharmaceutica), Merck-Serono and Pfizer. Each of the six companies pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease. For more information see http://www.ppu.mrc.ac.uk/overview/DSTT.php
Collaborator Contribution Benefits from DSTT collaboration The MRC-PPU benefits in many ways as a result of the DSTT research collaboration. 1. It provides an obvious translational outlet to enable our PIs to exploit their research findings. For example, any PI within the MRC-PPU can rapidly let all six pharmaceutical companies know about any new potential exciting research finding that they have made or any drug target that they have identified or validated. This can lead to major collaborations and stimulate one or more of the pharmaceutical companies to initiate a new drug discovery programme. 2. The research support received from this collaboration is invested in the PPU PIs research programmes and provides additional support to several of our Unit's Scientific service teams including our protein production teams, antibody generation team and cloning team. 3. We obtain key reagents including novel inhibitors, genetically modified cell or mice models from our DSTT pharmaceutical company collaborators. 4. The pharmaceutical companies we collaborate with provide us with important knowledge on the most critical research issues of the day for their drug development programmes. This feedback and industry perspective is extremely useful and helps maximise our overall competitiveness. It ensures that the drug discovery research programmes of the PPU PIs are focussed on addressing the most important questions for better understanding and treating disease. 5. The DSTT collaboration greatly benefits our students and postdocs by providing experience in working with industry via their direct involvement in collaborative experiments with pharmaceutical companies. This provides them with a unique insight into the high quality cutting edge research that is taking place within pharmaceutical companies and gives them an awareness of potential careers in industry. This is particularly important given that one of our main priorities is to train tomorrow's industrial researchers and ensure that the future workforce has the high quality scientific and research support skills that the UK economy will be dependent on.
Impact During the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
 
Description DSTT 
Organisation Johnson & Johnson
Department Janssen Pharmaceutica
Country Global 
Sector Private 
PI Contribution All the Programme Leaders in the MRC Protein Phosphorylation Unit have participated in a major collaboration with the pharmaceutical industry since 1998, termed The Division of Signal Transduction Therapy. From July 2003 to July 2008, the participating pharmaceutical companies were AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co, Merck-Serono and Pfizer. The collaboration was renewed for a further four years in July 2008 with five of these companies (Merck and Co leaving the consortium at this time). This collaboration was renewed for an unprecedented fourth time in July 2013 for a further four years with six pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janessen Pharmaceutica), Merck-Serono and Pfizer. Each of the six companies pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease. For more information see http://www.ppu.mrc.ac.uk/overview/DSTT.php
Collaborator Contribution Benefits from DSTT collaboration The MRC-PPU benefits in many ways as a result of the DSTT research collaboration. 1. It provides an obvious translational outlet to enable our PIs to exploit their research findings. For example, any PI within the MRC-PPU can rapidly let all six pharmaceutical companies know about any new potential exciting research finding that they have made or any drug target that they have identified or validated. This can lead to major collaborations and stimulate one or more of the pharmaceutical companies to initiate a new drug discovery programme. 2. The research support received from this collaboration is invested in the PPU PIs research programmes and provides additional support to several of our Unit's Scientific service teams including our protein production teams, antibody generation team and cloning team. 3. We obtain key reagents including novel inhibitors, genetically modified cell or mice models from our DSTT pharmaceutical company collaborators. 4. The pharmaceutical companies we collaborate with provide us with important knowledge on the most critical research issues of the day for their drug development programmes. This feedback and industry perspective is extremely useful and helps maximise our overall competitiveness. It ensures that the drug discovery research programmes of the PPU PIs are focussed on addressing the most important questions for better understanding and treating disease. 5. The DSTT collaboration greatly benefits our students and postdocs by providing experience in working with industry via their direct involvement in collaborative experiments with pharmaceutical companies. This provides them with a unique insight into the high quality cutting edge research that is taking place within pharmaceutical companies and gives them an awareness of potential careers in industry. This is particularly important given that one of our main priorities is to train tomorrow's industrial researchers and ensure that the future workforce has the high quality scientific and research support skills that the UK economy will be dependent on.
Impact During the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
 
Description DSTT 
Organisation Merck
Department Merck Serono
Country Germany 
Sector Private 
PI Contribution All the Programme Leaders in the MRC Protein Phosphorylation Unit have participated in a major collaboration with the pharmaceutical industry since 1998, termed The Division of Signal Transduction Therapy. From July 2003 to July 2008, the participating pharmaceutical companies were AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co, Merck-Serono and Pfizer. The collaboration was renewed for a further four years in July 2008 with five of these companies (Merck and Co leaving the consortium at this time). This collaboration was renewed for an unprecedented fourth time in July 2013 for a further four years with six pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janessen Pharmaceutica), Merck-Serono and Pfizer. Each of the six companies pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease. For more information see http://www.ppu.mrc.ac.uk/overview/DSTT.php
Collaborator Contribution Benefits from DSTT collaboration The MRC-PPU benefits in many ways as a result of the DSTT research collaboration. 1. It provides an obvious translational outlet to enable our PIs to exploit their research findings. For example, any PI within the MRC-PPU can rapidly let all six pharmaceutical companies know about any new potential exciting research finding that they have made or any drug target that they have identified or validated. This can lead to major collaborations and stimulate one or more of the pharmaceutical companies to initiate a new drug discovery programme. 2. The research support received from this collaboration is invested in the PPU PIs research programmes and provides additional support to several of our Unit's Scientific service teams including our protein production teams, antibody generation team and cloning team. 3. We obtain key reagents including novel inhibitors, genetically modified cell or mice models from our DSTT pharmaceutical company collaborators. 4. The pharmaceutical companies we collaborate with provide us with important knowledge on the most critical research issues of the day for their drug development programmes. This feedback and industry perspective is extremely useful and helps maximise our overall competitiveness. It ensures that the drug discovery research programmes of the PPU PIs are focussed on addressing the most important questions for better understanding and treating disease. 5. The DSTT collaboration greatly benefits our students and postdocs by providing experience in working with industry via their direct involvement in collaborative experiments with pharmaceutical companies. This provides them with a unique insight into the high quality cutting edge research that is taking place within pharmaceutical companies and gives them an awareness of potential careers in industry. This is particularly important given that one of our main priorities is to train tomorrow's industrial researchers and ensure that the future workforce has the high quality scientific and research support skills that the UK economy will be dependent on.
Impact During the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
 
Description DSTT 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution All the Programme Leaders in the MRC Protein Phosphorylation Unit have participated in a major collaboration with the pharmaceutical industry since 1998, termed The Division of Signal Transduction Therapy. From July 2003 to July 2008, the participating pharmaceutical companies were AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co, Merck-Serono and Pfizer. The collaboration was renewed for a further four years in July 2008 with five of these companies (Merck and Co leaving the consortium at this time). This collaboration was renewed for an unprecedented fourth time in July 2013 for a further four years with six pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janessen Pharmaceutica), Merck-Serono and Pfizer. Each of the six companies pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease. For more information see http://www.ppu.mrc.ac.uk/overview/DSTT.php
Collaborator Contribution Benefits from DSTT collaboration The MRC-PPU benefits in many ways as a result of the DSTT research collaboration. 1. It provides an obvious translational outlet to enable our PIs to exploit their research findings. For example, any PI within the MRC-PPU can rapidly let all six pharmaceutical companies know about any new potential exciting research finding that they have made or any drug target that they have identified or validated. This can lead to major collaborations and stimulate one or more of the pharmaceutical companies to initiate a new drug discovery programme. 2. The research support received from this collaboration is invested in the PPU PIs research programmes and provides additional support to several of our Unit's Scientific service teams including our protein production teams, antibody generation team and cloning team. 3. We obtain key reagents including novel inhibitors, genetically modified cell or mice models from our DSTT pharmaceutical company collaborators. 4. The pharmaceutical companies we collaborate with provide us with important knowledge on the most critical research issues of the day for their drug development programmes. This feedback and industry perspective is extremely useful and helps maximise our overall competitiveness. It ensures that the drug discovery research programmes of the PPU PIs are focussed on addressing the most important questions for better understanding and treating disease. 5. The DSTT collaboration greatly benefits our students and postdocs by providing experience in working with industry via their direct involvement in collaborative experiments with pharmaceutical companies. This provides them with a unique insight into the high quality cutting edge research that is taking place within pharmaceutical companies and gives them an awareness of potential careers in industry. This is particularly important given that one of our main priorities is to train tomorrow's industrial researchers and ensure that the future workforce has the high quality scientific and research support skills that the UK economy will be dependent on.
Impact During the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
 
Description DSTT renewal 2016 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution Boehringer-Ingelheim, GlaxoSmithKline and Merck-Serono - each company pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease.
Collaborator Contribution The MRC-PPU benefits in many ways as a result of the DSTT research collaboration.
Impact uring the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
Start Year 2016
 
Description DSTT renewal 2016 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Boehringer-Ingelheim, GlaxoSmithKline and Merck-Serono - each company pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease.
Collaborator Contribution The MRC-PPU benefits in many ways as a result of the DSTT research collaboration.
Impact uring the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
Start Year 2016
 
Description DSTT renewal 2016 
Organisation Merck
Department Merck Serono Ltd
Country United Kingdom 
Sector Private 
PI Contribution Boehringer-Ingelheim, GlaxoSmithKline and Merck-Serono - each company pays £600000 per annum over the four year period. The aim of the collaboration is to help the pharmaceutical companies accelerate the development of drugs that inhibit protein and lipid kinases and phosphatases with therapeutic potential for the treatment of disease.
Collaborator Contribution The MRC-PPU benefits in many ways as a result of the DSTT research collaboration.
Impact uring the collaboration, the Unit has helped to launch and/or accelerate many drug discovery programmes, some of which have entered human clinical trials. The collaboration led the Unit to develop the technology of protein kinase profiling which has developed into an industry worth over £100 million per annum. It also led to the creation of the European Division of Upstate Incorporated in Dundee which currently employs about 50 people. The Unit's first publication on protein kinase profiling was named in 2009 by the Institute for Scientific Information, Philadelphia as Europe's most cited paper in the field of Cel Biology from 1996-2007, with over 2,200 citations. During the collaboration, the Unit has filed 36 patents and 30 licenses have been taken up by the pharmaceutical industry. The DSTT is widely regarded as a model of how academia and industry should interact for which it received a Queen's Anniversary Award for Higher Education which was presented by the Queen and Duke of Edinburgh at Buckingham Palace in February 2006. GlaxoSmithKline have announced that their BRAF protein kinase inhibitor Dabrafenib (Tafinlar), has been approved by both the European Commission and the United States Food and Drug Administration for the treatment of unresectable or metastatic melanoma associated with the BRAF V600E mutation. Unresectable melanoma is that which cannot be removed by surgery, while metastatic melanoma is that which has spread to other parts of the body. The new drug was developed employing BRAF enzymes generated by researchers in the Division of Signal Transduction Therapy (DSTT) in the College of Life Sciences at Dundee.
Start Year 2016
 
Description Gerardo G 
Organisation National Autonomous University of Mexico
Country Mexico 
Sector Academic/University 
PI Contribution Undertaking biochemical analysis of WNK signalling pathways as well as provision of advice, reagents and technology
Collaborator Contribution Performing physiological measuremnts of WNK signalling pathway in mice
Impact Melo, Z., de los Heros, P., Cruz-Rangel, S., Vazquez, N., Bobadilla, N. A., Pasantes-Morales, H., Alessi, D. R., Mercado, A. and Gamba, G. (2013). N-terminal serine dephosphorylation is required for KCC3 cotransporter full activation by cell swelling. J Biol Chem 288, pp. 31468-31476 Castaneda-Bueno, M., Cervantes-Perez, L. G., Vazquez, N., Uribe, N., Kantesaria, S., Morla, L., Bobadilla, N. A., Doucet, A., Alessi, D. R. and Gamba, G. (2012). Activation of the renal Na+:Cl- cotransporter by angiotensin II is a WNK4-dependent process. Proc Natl Acad Sci U S A 109, pp. 7929-7934 Rafiqi, F. H., Zuber, A. M., Glover, M., Richardson, C., Fleming, S., Jovanovic, S., Jovanovic, A., O'Shaughnessy, K. M. and Alessi, D. R. (2010). Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med 2, pp. 63-75 San-Cristobal, P., Pacheco-Alvarez, D., Richardson, C., Ring, A. M., Vazquez, N., Rafiqi, F. H., Chari, D., Kahle, K. T., Leng, Q., Bobadilla, N. A., Hebert, S. C., Alessi, D. R., Lifton, R. P. and Gamba, G. (2009). Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A 106, pp. 4384-9
Start Year 2008
 
Description Gerardo Gamba 
Organisation National Autonomous University of Mexico
Country Mexico 
Sector Academic/University 
PI Contribution We have discussed collaborating. Dr Gamba will use many of our reagents and mice models to perform very detailed physiological analysis that the WNK pathway plays in the kidney and the control of blood pressure
Collaborator Contribution Dr Gamba will use many of our reagents and mice models to perform very detailed physiological analysis that the WNK pathway plays in the kidney and the control of blood pressure.We have discussed collaborating. Dr Gamba will use many of our reagents and mice models to perform very detailed physiological analysis that the WNK pathway plays in the kidney and the control of blood pressure
Impact 1 paper has been published so far (PMID: 19240212 ) We have just been awarded a new Wellcome Trust Joint Project Grant 2010-2013 ), £230,172 Geradro Gamba has just been awarded the Mexico Presidential Science Medal which is Mexico's most prestigious scientific award
Start Year 2008
 
Description Gerardo Gamba 
Organisation National Autonomous University of Mexico
Country Mexico 
Sector Academic/University 
PI Contribution We have discussed collaborating. Dr Gamba will use many of our reagents and mice models to perform very detailed physiological analysis that the WNK pathway plays in the kidney and the control of blood pressure
Collaborator Contribution Dr Gamba will use many of our reagents and mice models to perform very detailed physiological analysis that the WNK pathway plays in the kidney and the control of blood pressure.We have discussed collaborating. Dr Gamba will use many of our reagents and mice models to perform very detailed physiological analysis that the WNK pathway plays in the kidney and the control of blood pressure
Impact 1 paper has been published so far (PMID: 19240212 ) We have just been awarded a new Wellcome Trust Joint Project Grant 2010-2013 ), £230,172 Geradro Gamba has just been awarded the Mexico Presidential Science Medal which is Mexico's most prestigious scientific award
Start Year 2008
 
Description J Baselga 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution Undertaking functional studies on the SGK1 and SGK3 protein kinases in the field of cancer research
Collaborator Contribution Undertaking xenograph analysis of effects of Akt and SGK inhibitors on tumour development
Impact Bago, R., Sommer, E., Castel, P., Crafter, C., Bailey, F. P., Shpiro, N., Baselga, J., Cross, D., Eyers, P. A. and Alessi, D. R. (2016). The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. EMBO J 35, pp. 1902-1922 Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F. J., Kannan, S., Verma, C. S., Dickler, M., Chandarlapaty, S., Brogi, E., Alessi, D. R., Baselga, J. and Scaltriti, M. (2016). PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kalpha Inhibition. Cancer Cell 30, pp. 229-242
Start Year 2015
 
Description Jason B 
Organisation Ubiquigent
Country United Kingdom 
Sector Private 
PI Contribution Provision of reagents technolgy and advice to help ubiquigent provide services and reagents to its customers
Collaborator Contribution Ubiqigent sells our reagents to customers and also uses our advice reagents and expertise to help provide its customers with improved services
Impact .
Start Year 2010
 
Description Jessie rinehart Phosphorylation technology 
Organisation Yale University
Country United States 
Sector Academic/University 
PI Contribution Jessie Rinehart and his colleagues have developed new technology to express recombinant proteins that can be stoichiometrically phosphorylated at any residues
Collaborator Contribution We are putting this technology to use to tackle some important problems that our Unit is working on
Impact No papers yet-but this should yield some papers and perhaps additional funding opportunities in the future
Start Year 2013
 
Description Jon E 
Organisation University of Oxford
Department Wellcome Trust Centre for Human Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution Undertaking mutational analysis to help study crystal structures of the SGK3 protein kinase
Collaborator Contribution Crystallisation of the SGK3 protein kinase
Impact .
Start Year 2015
 
Description Kevin O 
Organisation University of Cambridge
Department Department of Anglo-Saxon, Norse and Celtic
Country United Kingdom 
Sector Academic/University 
PI Contribution provided genetically modified mice, reagents, technology and advice
Collaborator Contribution Undertook blood pressure measuremnts in mice and other physiological experiments
Impact Zhang, J., Siew, K., Macartney, T., O'Shaughnessy, K. M. and Alessi, D. R. (2015). Critical role of the SPAK protein kinase CCT domain in controlling blood pressure. Hum Mol Genet 24, pp. 4545-4558 Rafiqi, F. H., Zuber, A. M., Glover, M., Richardson, C., Fleming, S., Jovanovic, S., Jovanovic, A., O'Shaughnessy, K. M. and Alessi, D. R. (2010). Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med 2, pp. 63-75
Start Year 2009
 
Description Kevin O'Shaughnessy 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Measured blood pressure and ion levels in non-WNK-activatable SPAK knock-in mice
Collaborator Contribution Kevin O'Shaughnessy's group helped measure blood pressure as well as ion levels in the blood and urine in the wild type and SPAK knock-in mice. They also microdissected kidney tubules and immunoblotted these for SPAK as well as various other proteins using antibodies that we generated.
Impact A major paper describing this work has just been published Rafiqi, F.H., Zuber, A.M., Glover, M., Richardson, C., Fleming, S., Jovanovic, S., Jovanovic, A., O'Shaughnessy, K.M., and Alessi, D.R. (2010) Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Molecular Medicine 2, 63-75. This paper proves our hypothesis that inhibitors of SPAK and OSR1 should be well tolerated and can be used to lower blood pressure. Based on this MRCT have now started a major programme to develop drugs that inhibit SPAK/OSR1 for the treatment of blood pressure
Start Year 2009
 
Description Kris K 
Organisation Yale University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution Undertaking biochemical analysis of WNK signalling pathways as well as provision of advice, reagents and technology
Collaborator Contribution Performing physiological measuremnts of WNK signalling pathway in mice
Impact Zhang, J., Gao, G., Begum, G., Wang, J., Khanna, A. R., Shmukler, B. E., Daubner, G. M., de Los Heros, P., Davies, P., Varghese, J., Bhuiyan, M. I., Duan, J., Zhang, J., Duran, D., Alper, S. L., Sun, D., Elledge, S. J., Alessi, D. R. and Kahle, K. T. (2016). Functional kinomics establishes a critical node of volume-sensitive cation-Cl- cotransporter regulation in the mammalian brain. Sci Rep 6, pp. 35986 Alessi, D. R., Zhang, J., Khanna, A., Hochdorfer, T., Shang, Y. and Kahle, K. T. (2014). The WNK-SPAK/OSR1 pathway: Master regulator of cation-chloride cotransporters. Sci Signal 7, pp. re3 de Los Heros, P., Alessi, D. R., Gourlay, R., Campbell, D. G., Deak, M., Macartney, T. J., Kahle, K. T. and Zhang, J. (2014). The WNK-regulated SPAK/OSR1 kinases directly phosphorylate and inhibit the K+-Cl- co-transporters. Biochem J 458, pp. 559-573 San-Cristobal, P., Pacheco-Alvarez, D., Richardson, C., Ring, A. M., Vazquez, N., Rafiqi, F. H., Chari, D., Kahle, K. T., Leng, Q., Bobadilla, N. A., Hebert, S. C., Alessi, D. R., Lifton, R. P. and Gamba, G. (2009). Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A 106, pp. 4384-9
Start Year 2011
 
Description Kristopher Kahle Collaboration on ion cotransporters 
Organisation Harvard University
Country United States 
Sector Academic/University 
PI Contribution This collaboration is helping us understand the function of ion cotransporters that are regulated by the WNK siganlling patwhay
Collaborator Contribution They are providing expertise in this area of physiological research to support our work
Impact we are just submitting a research paper
Start Year 2012
 
Description MJFF LEAPS Collaboration to identify LRRK2 substrates 
Organisation Dana-Farber Cancer Institute
Country United States 
Sector Hospitals 
PI Contribution The purpose of this application was to identify a critical substrate of the LRRK2 Parkinson's kinase. My group coordinated the project and performed many of the key experiments. This was a very successful project that lead to the identification of Rthe first physiological substrates of LRRK2. The paper describing this result is currently under submission
Collaborator Contribution Matthias Mann group (Max Plank) undertook the critical mass spectrometer analysis that lead to the identification of the new LRRK2 substrate. GSK provided many of the key reagents and models that were needed for this project and were enormously supportive
Impact We have obtained over £1 million in new funding from the MJFF as well as a prestigious Network of Centres of Excellence in Neurodegeneration (CoEN) award in partnership with the MRC in the UK and DZNE in Germany to continue this research
Start Year 2012
 
Description MJFF LEAPS Collaboration to identify LRRK2 substrates 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution The purpose of this application was to identify a critical substrate of the LRRK2 Parkinson's kinase. My group coordinated the project and performed many of the key experiments. This was a very successful project that lead to the identification of Rthe first physiological substrates of LRRK2. The paper describing this result is currently under submission
Collaborator Contribution Matthias Mann group (Max Plank) undertook the critical mass spectrometer analysis that lead to the identification of the new LRRK2 substrate. GSK provided many of the key reagents and models that were needed for this project and were enormously supportive
Impact We have obtained over £1 million in new funding from the MJFF as well as a prestigious Network of Centres of Excellence in Neurodegeneration (CoEN) award in partnership with the MRC in the UK and DZNE in Germany to continue this research
Start Year 2012
 
Description MJFF LEAPS Collaboration to identify LRRK2 substrates 
Organisation Max Planck Society
Department Max Planck Martinsried
Country Germany 
Sector Academic/University 
PI Contribution The purpose of this application was to identify a critical substrate of the LRRK2 Parkinson's kinase. My group coordinated the project and performed many of the key experiments. This was a very successful project that lead to the identification of Rthe first physiological substrates of LRRK2. The paper describing this result is currently under submission
Collaborator Contribution Matthias Mann group (Max Plank) undertook the critical mass spectrometer analysis that lead to the identification of the new LRRK2 substrate. GSK provided many of the key reagents and models that were needed for this project and were enormously supportive
Impact We have obtained over £1 million in new funding from the MJFF as well as a prestigious Network of Centres of Excellence in Neurodegeneration (CoEN) award in partnership with the MRC in the UK and DZNE in Germany to continue this research
Start Year 2012
 
Description MRC HGU 
Organisation Medical Research Council (MRC)
Department MRC Human Genetics Unit
Country United Kingdom 
Sector Public 
PI Contribution advice and reagents and techical support
Collaborator Contribution They undertook the bulk of the experimentation
Impact .
Start Year 2010
 
Description Mike C 
Organisation University of Edinburgh
Department MRC Centre for Inflammation Research
Country United Kingdom 
Sector Public 
PI Contribution Undertook key experiments on TTBK2 kinase and advice and reagents and techical support
Collaborator Contribution Undertook detailed synapse function studies and generation of primary neurons
Impact Zhang, N., Gordon, S. L., Fritsch, M. J., Esoof, N., Campbell, D. G., Gourlay, R., Velupillai, S., Macartney, T., Peggie, M., van Aalten, D. M., Cousin, M. A. and Alessi, D. R. (2015). Phosphorylation of Synaptic Vesicle Protein 2A at Thr84 by Casein Kinase 1 Family Kinases Controls the Specific Retrieval of Synaptotagmin-1. J Neurosci 35, pp. 2492-2507
Start Year 2013
 
Description Nathanael Gray Chemical Biology 
Organisation Dana-Farber Cancer Institute
Department Department of Cancer Biology
Country United States 
Sector Academic/University 
PI Contribution We undertake the biological characterization of tool compounds that the Gray lab generates that target the enzymes we are working with
Collaborator Contribution We have thus far developed some state of the art new inhibitors that can be used to dissect biological roles of the Parkinson's disease LRRK2 protein kinase
Impact We have thus far co-authored 7 research papers and obtained two major Michael J Fox Foundation grant award to understand how mutations in LRRK2 cause Parkinson's disease
Start Year 2010
 
Description Neil B 
Organisation University of Oxford
Department Nuffield Department of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Undertaking mutational analysis to help study crystal structures of the WNK protein kinase
Collaborator Contribution Crystallisation of the WNK protein kinase
Impact Schumacher, F. R., Sorrell, F. J., Alessi, D. R., Bullock, A. N. and Kurz, T. (2014). Structural and biochemical characterization of the KLHL3-WNK kinase interaction important in blood pressure regulation. Biochem J 460, pp. 237-246
Start Year 2013
 
Description PI of the "Mouse Models to Accelerate Drug Discovery: A UK-China Network 
Organisation MRC Harwell
Country United Kingdom 
Sector Academic/University 
PI Contribution PI of the "Mouse Models to Accelerate Drug Discovery: A UK-China Network" MRC International Mouse Phenotyping Consortium. The aim of this is to generate and phenotype in detail over 100 genes that are involved in regulating ubiquitin biology and have been implicated in human disease.
Collaborator Contribution .
Impact .
Start Year 2012
 
Description Paul K F 
Organisation Avacta Group
Country United Kingdom 
Sector Private 
PI Contribution Provision of reagents technolgy and advice to generate new affimers to better study protein phosphorylation
Collaborator Contribution Use of our expertise and technology and reagents to develop novel affimers
Impact .
Start Year 2016
 
Description Role of LRRK2 phosphorylating Rab GTPase in Parkinson's 
Organisation Max Planck Society
Department Max Planck Martinsried
Country Germany 
Sector Academic/University 
PI Contribution I was the PI of a major MJFF collaboration that lead to the discovery that LRRK2 Parkinson's kinase's phosphorylates and inhibits multiple Rab GTPases. This was very exciting as this was the first physiological substrate for LRRK2 to be identified. Our laboratory coordinated the project and laed on many of the key experiments in this project
Collaborator Contribution The group of Matthias Mann undertook all the mass spectrometer experiments in this project and Susan Pfeffer's laboratory is undertaking the cell biology analysis
Impact Grant Income that funds research of two postdoctoral researchers in my lab
Start Year 2015
 
Description Role of LRRK2 phosphorylating Rab GTPase in Parkinson's 
Organisation Stanford University
Department Department of Biochemistry
Country United States 
Sector Academic/University 
PI Contribution I was the PI of a major MJFF collaboration that lead to the discovery that LRRK2 Parkinson's kinase's phosphorylates and inhibits multiple Rab GTPases. This was very exciting as this was the first physiological substrate for LRRK2 to be identified. Our laboratory coordinated the project and laed on many of the key experiments in this project
Collaborator Contribution The group of Matthias Mann undertook all the mass spectrometer experiments in this project and Susan Pfeffer's laboratory is undertaking the cell biology analysis
Impact Grant Income that funds research of two postdoctoral researchers in my lab
Start Year 2015
 
Description Role of LRRK2[R1441G] mutations in Parkinson's 
Organisation University of Hong Kong
Department Li Ka Shing School of Medicine
Country Hong Kong 
Sector Academic/University 
PI Contribution The group of Prof Ho have generated an LRRK2[R1441G] knock-in mouse that mimics one of the major disease causing mutations in human Parkinson's patients. We have initiated a major collaboration to discover how this mutation induces phosphorylation of Rab isoforms by LRRK2 and work out how this is linked to development of Parkinson's disease.
Collaborator Contribution Providing LRRK2[R1441G] knock-in mouse and helping with some of the experiments
Impact none as yet-but we should have some interesting data that should be published in 2016
Start Year 2015
 
Description Shinichi U 
Organisation Tokyo Medical and Dental University
Department Department of Neurology and Neurological Science
Country Japan 
Sector Academic/University 
PI Contribution Undertaking biochemical analysis of WNK signalling pathways as well as provision of advice, reagents and technology
Collaborator Contribution Performing physiological measuremnts of WNK signalling pathway in mice
Impact Nishida, H., Sohara, E., Nomura, N., Chiga, M., Alessi, D. R., Rai, T., Sasaki, S. and Uchida, S. (2012). Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Activates the WNK-OSR1/SPAK-NCC Phosphorylation Cascade in Hyperinsulinemic db/db Mice. Hypertension 60, pp. 981-990 Oi, K., Sohara, E., Rai, T., Misawa, M., Chiga, M., Alessi, D. R., Sasaki, S. and Uchida, S. (2012). A minor role of WNK3 in regulating phosphorylation of renal NKCC2 and NCC co-transporters in vivo. Biol Open 1, pp. 120-127 Susa, K., Kita, S., Iwamoto, T., Yang, S. S., Lin, S. H., Ohta, A., Sohara, E., Rai, T., Sasaki, S., Alessi, D. R. and Uchida, S. (2012). Effect of heterozygous deletion of WNK1 on the WNK-OSR1/ SPAK-NCC/NKCC1/NKCC2 signal cascade in the kidney and blood vessels. Clin Exp Nephrol 16, pp. 530-538 Chiga, M., Rafiqi, F. H., Alessi, D. R., Sohara, E., Ohta, A., Rai, T., Sasaki, S. and Uchida, S. (2011). Phenotypes of pseudohypoaldosteronism type II caused by the WNK4 D561A missense mutation are dependent on the WNK-OSR1/SPAK kinase cascade. J Cell Sci 124, pp. 1391-1395
Start Year 2011
 
Description Timothy G 
Organisation University of Pittsburgh
Department Pittsburgh Institute for Neurodegenerative Diseases
Country United States 
Sector Hospitals 
PI Contribution Provisions of Regeants, technology and experimental support to measure the impact that rotenone has on LRRK2 protein kinase activity
Collaborator Contribution Undertaking assays to measure LRRK2 and Rab phosphorylation using reagents provided by us
Impact ,
Start Year 2016
 
Description We initiated a major Collaboration with Nathanael Gray at the Dana Farber Cancer insititute to develop LRRK2 inibitors 
Organisation Dana-Farber Cancer Institute
Department Department of Cancer Biology
Country United States 
Sector Academic/University 
PI Contribution We were able to help Nathanael Gray develop a potent LRRK2 inhibitor and we undertook all the in vivo testing of this inhibitor to demonstrate that it specifically inhibited LRRK2 in vivo
Collaborator Contribution I as well as my colleagues at the MRC-PPU have many additional collaborations with Nathaneal Gray who is an amazing chemical biologist. The work he is doing has the possibility to greatly aid our research. We are even now trying to recruit him to Dundee!
Impact Grant application 2011-2013 Michael J. Fox Foundation for Parkinson's Research (MJFF) Project Grant, (Joint with Nathanael Gray [Main Applicant]), Dundee MRC-PPU share US$254,400 Plus the following 2 papers 181. Deng, X., Dzamko, N., Prescott, A.R., Davies, P., Liu, Q., Yang, Q., Lee, J.D., Patricelli, M.P., Nomanbhoy, T.K., Alessi, D.R. and Gray, N.S. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology 7, 203-205. Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S., Machleidt, T., Xie, T., Marto, J.A., NKim, N., Sim, T., Laughlin, J.D., Park, H., LoGrasso, P. V., Patricelli, M., Nomanbhoy, T.K., Sorger, P/K., Alessi, D.R. and Gray, N.S. (2011) Discovery of potent and selective covalent inhibitors of JNK. Chemistry & Biology In the Press
Start Year 2009
 
Description We initiated a major Collaboration with Nathanael Gray at the Dana Farber Cancer insititute to develop LRRK2 inibitors 
Organisation Dana-Farber Cancer Institute
Department Department of Cancer Biology
Country United States 
Sector Academic/University 
PI Contribution We were able to help Nathanael Gray develop a potent LRRK2 inhibitor and we undertook all the in vivo testing of this inhibitor to demonstrate that it specifically inhibited LRRK2 in vivo
Collaborator Contribution I as well as my colleagues at the MRC-PPU have many additional collaborations with Nathaneal Gray who is an amazing chemical biologist. The work he is doing has the possibility to greatly aid our research. We are even now trying to recruit him to Dundee!
Impact Grant application 2011-2013 Michael J. Fox Foundation for Parkinson's Research (MJFF) Project Grant, (Joint with Nathanael Gray [Main Applicant]), Dundee MRC-PPU share US$254,400 Plus the following 2 papers 181. Deng, X., Dzamko, N., Prescott, A.R., Davies, P., Liu, Q., Yang, Q., Lee, J.D., Patricelli, M.P., Nomanbhoy, T.K., Alessi, D.R. and Gray, N.S. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology 7, 203-205. Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S., Machleidt, T., Xie, T., Marto, J.A., NKim, N., Sim, T., Laughlin, J.D., Park, H., LoGrasso, P. V., Patricelli, M., Nomanbhoy, T.K., Sorger, P/K., Alessi, D.R. and Gray, N.S. (2011) Discovery of potent and selective covalent inhibitors of JNK. Chemistry & Biology In the Press
Start Year 2009
 
Description Youcef M 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Undertaking assays to study inhibitors of the WNK signalling pathway as well as advice, reagents and technology
Collaborator Contribution Generation of novel kinase inhibitors that tartget components of the WNK signalling pathway
Impact .
Start Year 2015
 
Title LRRK2 assay 
Description A method for identifying a compound expected to be useful in modulating a LRRK2 protein kinase activity. 
IP Reference EP2132326 
Protection Patent granted
Year Protection Granted 2009
Licensed No
Impact Novel and improved (earlier filing-A813/2087) substrate for LRRK2, a kinase implicated in Parkinson's Disease.
 
Title LRRK2 assay 
Description A method for identifying a compound expected to be useful in modulating a LRRK2 protein kinase activity. 
IP Reference EP2132326 
Protection Patent granted
Year Protection Granted 2009
Licensed No
Impact Novel and improved (earlier filing-A813/2087) substrate for LRRK2, a kinase implicated in Parkinson's Disease.
 
Title This application concerns the discovery and use of MO25 isoforms as activators of STE20 kinases such as SPAK, OSR1 and MST isoforms 
Description Our research has lead to the discovery of two new drug targets for the treatment of hypertension that are protein kinases termed SPAK and OSR1. Several drug companies as well as MRC Technology as screening for inhibitors of SPAK and OSR1 for the treatment of hypertesnion. Here we have discovered that SPAk and OSR1 interact with a regulatory subunit termed MO25. This results in over 100-fold activation of SPAK and OSR1. This patent protects the discovery of MO25 subunits and there use as a tool to activate SPAK and OSR1. Presumably all companies screening for SPAK and OSR1 would need to use MO25 subunits to activate SPAK/OSR1 
IP Reference GB1104012.8 
Protection Patent application published
Year Protection Granted 2011
Licensed No
Impact This has opened up a new area of this field of research that we and others are now pursuing
 
Title This application concerns the discovery and use of phosphospecific antibodies that detect the activated forms of PINK1 and Parkin 
Description This describes a new method that could help with the diagnosis and treatment of Parkinson's disease 
IP Reference GB1206382.2 
Protection Patent application published
Year Protection Granted 2012
Licensed No
Impact We are in discussions with Pahramceutical comapnies
 
Title WNK assay 
Description Activation and assay of the WNK-acttvated SPAK and OSR1 kinases 
IP Reference US2008286809 
Protection Patent granted
Year Protection Granted 2008
Licensed No
Impact WNK (With No lysine Kinase) kinases have been implicated as a potential target to treat hypertension. Mutations in the human genes encoding WNK1 and the related protein kinase WNK4, are the cause of Gordon's hypertension syndrome. Application discloses the naturally occurring substrates for WNK1 and 4 and describes an assay to identify modulators of their activity., National phase
 
Title LRRK2 assay 
Description New optimised assay to assess LRRK2 function 
Type Support Tool - For Medical Intervention
Current Stage Of Development Initial development
Year Development Stage Completed 2009
Development Status Under active development/distribution
Impact Patent filed by MRC. Many companies using this assay for drug screening programs to develop LRRK2 inhibitors for the treatment of Parkinson's disease 
 
Description 20 Year Celebration of the DSTT 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact During an event at Dundee's recently opened V&A museum to celebrate the 20 year anniversary of the DSTT I gave an interview with STV news.
Year(s) Of Engagement Activity 2018
 
Description 7 2017 CDKL5 Forum Meeting - Boston, November 29-30 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Stimulate research and understanding into CDKL5 deficiency disease and stimulate new treatments to be developed
Year(s) Of Engagement Activity 2017
 
Description Another Partner for LRRK2: Will This Relationship Endure? 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Comment and perspective on the significance of a paper describing a new LRRK2 protein interactor to researchers (Martin, et al. Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson's Disease. Cell. 2014 Apr 10;157(2))


Dr. Alessi's comments provide perspective regarding novel findings on the kinase LRRK2 and their impact in the Parkinson's disease research field.
Year(s) Of Engagement Activity 2014
URL http://www.alzforum.org/news/research-news/another-partner-lrrk2-will-relationship-endure
 
Description Attendance at the Scottish Parliament - MRC 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/politicians
Results and Impact Myself, Professor John Rouse and Dr Paul Davies attended an event in the Scottish Parliament on 6th February to support the Medical Research Council's investment in science in Scotland and to present the work that we are doing in the MRC-PPU to MSPs.
Year(s) Of Engagement Activity 2019
 
Description Cafe Science Presentation by Miratul Muqit 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Cafe Science attracts a diverse range of speakers in all branches of science addressing audiences of around 100 members of the public. Miratul Parkinson's disease and recent research advances

Miratul's talk was publicised in the Dundee Courier and Evening telegrapgh
Year(s) Of Engagement Activity 2011
 
Description Discussion with influential Scottish GP 21/12/2015 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact 21 Dec 2015
I spent 2.5 hours talking to Dr James Colville Laird and his daughter Alisa Laird about the importance of protein phosphorylation and ubiquitylation in medical research. I also showed them round the MRC-PPU and School of Life Sciences research facilities. Dr Laird who is one of Scotland's most well know general practitioner and has greatly contributed to develop emergency medicine training for rural health professionals practice for accident and emergency


Too early to say
Year(s) Of Engagement Activity 2015
 
Description Dolly scientist backs research drive to tackle Parkinson's disease - University of Dundee Press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Professor Sir Ian Wilmut - who led the team that created Dolly the sheep - has backed an initiative to tackle Parkinson's disease, after being diagnosed with the condition.

The eminent scientist announced his diagnosis today - World Parkinson's Day - ahead of the launch of a major research programme that will see experts at the Universities of Edinburgh and Dundee join forces in the quest to better understand the disease. They will set up infrastructure to enable the first trials in Scotland in a generation for therapies that aim to slow down Parkinson's disease progression.

The new Dundee-Edinburgh Parkinson's Research Initiative aims to probe the causes of disease and translate scientific discoveries into new therapies. The ultimate goal is to find new approaches to predict and prevent Parkinson's, and to facilitate clinical testing of therapies aimed at slowing or reversing disease progression.

Professor Dario Alessi, of the University of Dundee, said, "All attempts to slow the progression of Parkinson's have thus far failed. Surprisingly today's most widely utilised Parkinson's drug levodopa was first used in the clinic in 1967.

"In recent years, our knowledge of the genetics and biology underlining Parkinson's disease has exploded. I feel optimistic and it is not unrealistic that with a coordinated research effort, major strides towards better treating Parkinson's disease can be made."

Parkinson's disease is a progressive condition caused by damage to specific cells in the brain. It affects movement and is often associated with involuntary shaking. Therapies that reduce symptoms can help to prolong quality of life, but currently there are no treatments to slow or halt the progression of the disease.

At present, Scottish patients seeking to take part in clinical trials of treatments that could delay disease progression are required to travel to centres in England or Wales, or even abroad.

Professor Wilmut said, "Initiatives of this kind are very effective not only because they bring more people together, but because they will include people with different experience and expertise. It was from such a rich seedbed that Dolly developed and we can hope for similar benefits in this project."

Dolly the sheep was created at The Roslin Institute in 1996 by a multidisciplinary research team led by Professor Wilmut. She was the first clone of an animal from an adult cell and her birth turned scientific thinking on its head.

It showed that cells from anywhere in the body could be made to behave like a newly fertilised egg - something that scientists had thought was impossible.

This breakthrough paved the way for others to develop a method of using adult cells to produce reprogrammable cells that could develop into any kind of tissue in the body - so called induced pluripotent stem cells, or iPSCs.

These cells hold great promise as therapies because of their potential to repair damaged tissues. The first clinical trials of iPSCs for Parkinson's disease are to begin in Japan later this year.

Dr Tilo Kunath, of Edinburgh's Medical Research Council Centre for Regenerative Medicine, said, "People with Parkinson's urgently require access to earlier and more accurate diagnosis, better prediction of how their disease will progress, and most importantly, the opportunity to participate in clinical trials of new treatments. This new research partnership aims to make these hopes a reality for people in Scotland."

There are more than 12,000 people living with Parkinson's disease in Scotland. Across the UK, the number is expect to double in the next 50 years as the population grows and people live longer.

The Dundee-Edinburgh Parkinson's Research Initiative will be formally launched at a public event at the Royal College of Physicians of Edinburgh on Friday 13 April.
Year(s) Of Engagement Activity 2018
 
Description Dundee Research Interest Group (DRIG) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Myself and several members of my lab, including Dr Esther Sammler and Dr Paul Davies participated in a Parkinson's patients event organised by the Dundee Research Interest Group (DRIG) within the SLS on 18th January 2019.
Year(s) Of Engagement Activity 2019
 
Description Dundee Science Festival 2014 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact As a part of the one of the events organized by the MRC-PPU - The Wonders of the Brain: Big and Small! - visitors were encouraged to partake in a trivia challenge, all as they journeyed through the exhibit where they learned about the brain, viewed models from different species, and evaluated example MRIs and illustrations that highlighted changes that occur during disease. The games that were a part of this exhibit were also a great hit as children matched neurotransmitter 'vesicles' with the proper receptor, made neurons out pipe-cleaner, made their very own thinking caps and 'trained their brain' using memory and motor games.

The MRC PPU hosted 2 large events at the 2014 Dundee Science Festival and engaged the public -- from young children, to parents and grandparents. Through trivia and direct interaction, the public learned about the impact of MRC PPU research.
Year(s) Of Engagement Activity 2014
 
Description Edinburgh Parkinson's seminar that was delivered by Giovanni Mallucci 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact PRC PPU Unit co-sponsored the Edinburgh Parkinson's seminar that was delivered by Giovanni Mallucci in which 300 patients and family members attended. Professor Dario Alessi gave the vote of thanks at the end of the seminar.
Year(s) Of Engagement Activity 2018
 
Description Forthill Primary School Visit - June, 2014 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Scientists and support staff from the MRC PPU recently enjoyed a visit with a P3 class at Forthill Primary for a fun morning of hands on experiments. Overall, the morning proved to be a big hit and provided a fun introduction to hands-on general science experiments for the P3 children.


There was plenty of loud vocal appreciation from the children and assurances from many that scientist is now their primary career choice.
Year(s) Of Engagement Activity 2014
 
Description Helped organise a Visit to our Unit of ~40 parkinson's patients + family 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact ~40 patients and family attended a Q&A session on our Parkinson's disease research that was then followed by a visit of our research facilities. This was part of the MRC centenary celebration events

We obtained very positive feedback
Year(s) Of Engagement Activity 2013
URL http://www.ppu.mrc.ac.uk/news_and_seminars/mrc_unit_news.php
 
Description Interview to discuss LRRK2 and Parkinson's Disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Interview with "Tomorrow Edition" to discuss Parkinson's disease and LRRK2.
Year(s) Of Engagement Activity 2018
URL https://tmrwedition.com/2018/09/18/interview-with-biochemist-and-lrrk2-expert-prof-dario-alessi/
 
Description Interviews to mark the 50th PMC DSTT meeting with our pahramceutical company collaborators 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact helped publicize our DSTT pharmaceutical company collaboration
Year(s) Of Engagement Activity 2013
URL http://www.ppu.mrc.ac.uk/news_and_seminars/mrc_unit_news.php
 
Description MRC Festical of Medical Research Inside Out Science Open Day 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact MRC Festival of Medical Research Inside Out Science Open day involved researchers from the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) and MRC Doctoral Training Programme students (from the Schools of Life Sciences and Medicine at the University of Dundee). The MRC Festival aimed to inform, inspire and stimulate thinking about medical research. Our event was held within the School of Life Sciences and involved seven table top engagement activities, five ten-minute accessible science talks given by PhD students and early career researchers, three lab tours and three videos about the scientific work of the Unit on loop with visitors. There were two new activities called Chromatography and Stem Cell Game trialled that were developed by MRC PPU staff and students plus previously developed activities. Prior to the open day event, a primary six class at Glebelands Primary School attended a 90 minute session to give valuable feedback on talks and new activities.

Members from my lab who participated were;
Elena Purlyte - PhD Student
Alexia Kalogeropoulou - PhD Student
Jordana Freemantle - PhD Student

Overall, 129 members of public (generally family groups) were reached with 103 people visiting on the day, a further 24 Primary Six pupils and their two teachers who gave feedback on the new talks and activities ahead of the event.
The event met a number of the objectives and key messages from the 2018 - 2023 MRC Protein phosphorylation and ubiquitination Public Engagement and Communications Plan which were:

Communications Objectives
1) Generate interest in science as a career path for young people in Dundee to reveal opportunities and make science accessible.
2) Share the unit's research expertise with non-scientific communities to raise awareness of the importance of basic research in understanding health and disease.

Key Messages
1) Basic research is vital - before we can develop new medicines we first need to understand how the body works in health and disease.
2) MRC PPU is an outstanding environment to pursue phosphorylation or ubiquitylation research.
3) As scientists we value new ideas and are open to sharing our work with all who have an interest in it.

Feedback
The visitors to the event were a mixture of ages which included family groups (children under 16 years) and adults up to 70 years of age. Feedback indicated that they enjoyed themselves overall and said they would come to a similar event again. Highlights included a game developed on the topic of Stem Cells and the laboratory tours. Around a third of visitors polled had not attended a University of Dundee event before indicating we were reaching new audiences.
The talks in particular stimulated a number of questions from the audience such as:
• How long does it take for a cell to divide?
• What would happen if you lost all your amino acids?
• Is it only older people who get Parkinson's?
• What is it about not being obese that helps protect you from Alzheimer's?
• What does wildtype mean?

Participants reported having a positive experience, they all said they'd do it again and that they'd recommend a colleague take part too.
Year(s) Of Engagement Activity 2016,2018
 
Description MRC-PPU Collaboration with Baldragon Academy 2014 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact The Medical Research Council's Protein Phosphorylation Ubiquitylation Unit (MRCPPU), part of The University of Dundee, has prioritized public engagement in an effort to engage the general public and ensure that the research activities and breakthroughs are communicated to the community. Of equal importance in these communication efforts is educational outreach to students within the Dundee community.

Thus, during session 2014 -2015 and 2015-2016 school year, the MRC-PPU will partner with a local secondary school -- Baldragon Academy (BA). Teachers in BA's Science Department will collaborate with scientists at the MRC-PPU in an educational outreach effort (see Appendix 1). The purpose of this project is to increase interest and engagement in science and related careers. It will be starting in August 2014 with the S1 pupils.

Scientists from the unit will be working with the pupils on a monthly basis at the school during their science classes and will be providing them with opportunities to take part in various science experiments and demonstrations (aligned with Scotland's Curriculum for Excellence). The scientists are leaders in their field of research and as such come from all over the world. They are currently based in Dundee."


Thus far, student have been very enthusiastic about the labs and very receptive to the volunteers. They have asked a multitude of quesitons and have even asked volunteers back to visit.
Year(s) Of Engagement Activity 2014
 
Description MRC-PPU Collaboration with Baldragon Academy 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact The Medical Research Council's Protein Phosphorylation Ubiquitylation Unit (MRCPPU), part of The University of Dundee, has prioritized public engagement in an effort to engage the general public and ensure that the research activities and breakthroughs are communicated to the community. Of equal importance in these communication efforts is educational outreach to students within the Dundee community.

Thus, during session 2014 -2015 and 2015-2016 school year, the MRC-PPU will partner with a local secondary school -- Baldragon Academy (BA). Teachers in BA's Science Department will collaborate with scientists at the MRC-PPU in an educational outreach effort (see Appendix 1). The purpose of this project is to increase interest and engagement in science and related careers. It will be starting in August 2014 with the S1 pupils.

Scientists from the unit will be working with the pupils on a monthly basis at the school during their science classes and will be providing them with opportunities to take part in various science experiments and demonstrations (aligned with Scotland's Curriculum for Excellence). The scientists are leaders in their field of research and as such come from all over the world. They are currently based in Dundee.

Thus far, student have been very enthusiastic about the labs and very receptive to the volunteers. They have asked a multitude of questions and have even asked volunteers back to visit. We have also had numerous students of different ages from the school ask to participate in work experience activities to learn more about the Unit and science in general.
Year(s) Of Engagement Activity 2015
 
Description Mythbusters Case Study for Association of the British Pharmaceutical Industry (ABPI) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Writer from ABPI contacted Dr. Alessi to learn more about the DSTT model so that she might utilize it as an example of a successful collaboration between the pharmaceutical industry and a university. This is for a myth busters campaign the ABPI putting together exploring the common myths around the pharmaceutical industry. The myth she wished to use this case study for is: Universities create valuable discoveries and then we (the pharmaceutical industry) swoop in and take all the credit.

Highlighting the DSTT model provided ABPI with a concrete example of the positive impact public/private partnerships between academia and industry can have for moving therapeutics forward.
Year(s) Of Engagement Activity 2014
 
Description Open Letter - Scottish Referendum 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A group of eminent Scottish medical experts have warned that independence would seriously damage research funding for Scotland's universities and medical schools.

The open letter from 14 experts, including senior staff from all five of the country's main medical schools, said they had grave concerns that Scotland's world-leading biomedical and life sciences research would suffer if Scotland sleepwalks into leaving the UK.

The letter, coordinated by Sir David Carter, a former chief medical officer in Scotland, said Scottish universities did disproportionately well out of the UK's research funding system and from the UK's charitable and medical foundation grants.

Dr. Alessi's signature and viewpoints, while his own, brought to light in the general public, the potential deleterious impact a 'Yes' vote would have had upon Scottish scientific research funding.
Year(s) Of Engagement Activity 2014
URL http://www.theguardian.com/politics/2014/may/23/scottish-independence-research-funding-medical-exper...
 
Description Parkinson's Fundraising Musical Concert - 22/11/15 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact MRC PPU investigators (Drs. Sammler, Muqit and Das) attended on behalf of the Unit. Dr. Sammler spoke about the Unit's research and engaged with patients.

This was a light-hearted musical event whose goal was truly for attendees to enjoy their time, all with the purpose of raising funds for Parkinson's research.
Year(s) Of Engagement Activity 2015
 
Description Parkinson's Open Day 2013 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact As part of the MRC's week of Centenary Celebrations, the MRC-PPU held an Open Day on Parkinson's disease to showcase cutting research being undertaken at the Unit that one day may lead to new treatments for this devastating condition. Highlights included discussions about current targets implicated in PD and the potential for disease modification, as well as an explanation of the the drug development process.


Visitors were very enthusiastic and asked many questions during the talks as well as during the lab tours. As this was the first time for many, they appreciated learning about the breadth of research -- from basic science to therapeutic development -- that is being undertaken at The University of Dundee.
Year(s) Of Engagement Activity 2013
 
Description Parkinson's Open Day 2014 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact Given the positive feedback from a previous event, the MRC-PPU held an Open Day on Parkinson's disease to showcase cutting research being undertaken at the Unit that one day may lead to new treatments for this devastating condition. Highlights included discussions about current targets implicated in PD and the potential for disease modification, as well as an explanation of the the drug development process.


Visitors were very enthusiastic and asked many questions during the talks as well as during the lab tours. As this was the first time for many, they appreciated learning about the breadth of research -- from basic science to therapeutic development -- that is being undertaken at The University of Dundee.
Year(s) Of Engagement Activity 2014
 
Description Parkinson's Patient/Parkinson's Uk organised event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Gave a talk on LRRK2 in Parkinson's at a Parkinson's Patient/Parkinson's Uk organised event.
Year(s) Of Engagement Activity 2018
 
Description Parkinson's UK Patient Group Visit - 28/2/15 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact Dr. Alessi gave a public engagement talk on Saturday morning (28th Feb 2015) to a group of ~30 Parkinson's patients and their families. This is the Edinburgh Branch of Parkinson's UK and the group called the ERIG (Edinburgh Research Interest Group).

Professor Alessi gave an hour talk on the importance of research in Parkinson's disease emphasising what your Unit was doing and why he thought that this was very important. The talk lasted about an hour and he spent about 90 min talking to the members of the group. The talk was held at the SCRM building at the University of Edinburgh Little France. Patients asked numerous questions about the current state of disease modifying treatments for Parkinson's disease
Year(s) Of Engagement Activity 2015
 
Description Parkinson's UK Supporters Event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Discussing mine and the units research and projects to Parkinson's supporters at the Parkinson's UK Supporters Event on 2nd July 2018
Year(s) Of Engagement Activity 2018
 
Description Presented the Betsy Sinclair Memorial Lecture of Diabetes UK, Edinburgh 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact This is a special lecture held annually in Edinburgh that is organised by Diabetes UK

Had a lot of positive feedback from audience
Year(s) Of Engagement Activity 2009
 
Description Public Lecture by Miratul Muqit 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact A talk describing recent research progress in parkinson's disease with around 50 patients and their relatives as the audience

Miratul got lots of positive feedback from organisers
Year(s) Of Engagement Activity 2012
 
Description Radio interview with Tay fm 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Conducted a Radio interview with local station Tay FM to discuss the recent press release by University of Dundee, titled "Dolly scientist backs research drive to tackle Parkinson's disease"
Year(s) Of Engagement Activity 2018
 
Description Request for Comment About The Scottish Referendum - Blakeway Productions 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Journalist working for Blakeway Productions spoke with Dr. Alessi in an off the record capacity and for background research. as they are producing a television current affairs programme for Channel 4, focussing on the Scottish Independence Referendum. They were examining the political campaigns on both sides of the debate and the way in which that debate is being conducted. Additionally, they were keen to speak with Dr. Alessi regarding the open letter that was published in May, 2014 about concerns around research in an independent Scotland.


Dr. Alessi's signature and viewpoints, while his own, brought to light in the general public, the potential deleterious impact a 'Yes' vote would have had upon Scottish scientific research funding.
Year(s) Of Engagement Activity 2014
 
Description Review of publication for an online scientific forum 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Comment and perspetive on importance of LRRK2 paper to PD research (Skibinski, et al. 2014; J.Neurosci 34(2):418-433)

This summary lends a scientific perspective pertaining to the specific publication, to the research community.
Year(s) Of Engagement Activity 2014
URL http://www.alzforum.org/papers/mutant-lrrk2-toxicity-neurons-depends-lrrk2-levels-and-synuclein-not-...
 
Description TV Interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Gave various interviews to Radio and TV on a Parkinson's Disease paper that we had published

Helped disseminate our findings to Parkinson's patients
Year(s) Of Engagement Activity 2013
 
Description TV and Radio Interviews publicising renewal of our MRC core funding of 24 M 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Interviews

This helped publicize our Units activities
Year(s) Of Engagement Activity 2013
URL http://www.ppu.mrc.ac.uk/news_and_seminars/mrc_unit_news.php
 
Description Talk to Edinburgh Parkinson's research group (Miratul Muqit) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact A presentation of Parkinson's disease and recent research progress including work undertaken by Parkinson's UK supported research in our laboratory.

Miratul's talk has been uploaded for general public access see-
http://www.edinburghparkinsons.org/branch_news.php
Year(s) Of Engagement Activity 2012
 
Description To be or not to be Independent, that is the Question! (Lab Times) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact the potential impact the referendum could have for research in Scotland. This is not intended to defend either side, but simply a look at what it could mean for the Scottish scientific community.
I believe you jointly signed an open letter expressing your concerns over the Yes vote. I was wondering if you would be able to comment on this matter, particularly in terms of funding available and areas of potential growth for Scotland?


Dr. Alessi's signature and viewpoints, while his own, brought to light in the general public, the potential deleterious impact a 'Yes' vote would have had upon Scottish scientific research funding.
Year(s) Of Engagement Activity 2014
URL http://www.labtimes.org/editorial/e_523.lasso
 
Description University of Dundee Open Doors Day 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact The goal of Open Doors Day is to inform the public, especially locally in Dundee, about the kinds of research being carried out at the University. This involved volunteers speaking with visitors -- young and old -- as well as engaging children with games mean to teach as well as have fun.

All visitors were enthusiastically engaged in this event and visited each of the PPU stands focused on both Neurodegeneration and Cancer.
Year(s) Of Engagement Activity 2015
 
Description Visit by Labor MP Alistair Darling and MSP Jenny Marra 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Given the importance of medical science research at The University of Dundee, Alistair Darling, MP and the 'Better Together' campaign visited the DSTT to better understand its pivotal role in industry/academic collaborations.


Highlighing the DSTT model provided Mr. Darling with a concrete example of the positive impact public/private partnerships between academia and industry can have for moving therapeutics forward.
Year(s) Of Engagement Activity 2014
 
Description Visit from Annie MacLeod, Scotland Director for Parkinson's UKs 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact Annie MacLeod, Scotland Director for Parkinson's UK visit our lab on Thursday 7th March. The purpose of Annie's visit was to find out more about our research. Annie also had a tour of our labs as well as meeting with myself, Miratul Muqit and Esther Sammler.
Year(s) Of Engagement Activity 2019